High Risk, High Returns (Biotech Investing Newsletter)
Systima CapitalBiotech Investing Newsletter: 2x your money, one biotech catalyst at a time A biotech analyst (ex-Deutsche Bank, ex-consulting, PhD) dissects biotech catalysts worth investing in!
| Platform |  | Pricing | Only free issues | Publishes | Twice weekly |
|---|---|---|---|---|---|
| Issues | 21 | Subscribers | Read | manosmastorakisphd.substack.com |
Curious about how many subscribers High Risk, High Returns has or want to find similar newsletters? Reletter has got you covered. We collated all the information we could find from across the web in our database of over three million newsletters.
Check the email archives, get traffic estimates, engagement scores and more to discover the best advertising opportunities.
Our search tool helps you locate relevant newsletters for any topic and compare their stats for better sponsorship decisions.
Latest Issues
Recent posts by this newsletter. Browse the email archive.
Post #19: Karyopharm's P3 readout (March 2026) about to shake things up in myelofibrosis. We're cautious
Front‑line myelofibrosis (MF) is about to get its next big test. Within weeks, Karyopharm is expected to deliver top‑line data from SENTRY (XPORT‑MF‑034), the phase 3 trial of selinexor plus ruxolitinib in JAK‑inhibitor–naïve MF. The readou...
Post $18: BREAKING: Portfolio Update - Sold $AZN + $BIOA
As promised in my 2025 wrap post, 2026 will see more actionable insights on how I will be managing my biotech portfolio moving forward, including what I buy and what I sell - at a minimum.
2026: Year of the Fire Horse brings us countless of biotech catalysts and opportunities
What a year it’s been! From leaving my full time gig as a pharmaceuticals/biotechnology equity research analyst at Deutsche Bank, to embracing independent research focusing on small/mid cap biotech stocks and launching my own Substack newsl...
Authors
The writers behind this newsletter.
PhD Genetics, MSc Finance, ex-Deutsche Bank Pharma/Biotech sellside research, R&D consulting in biotech. Clinical biotech catalyst-driven investing. "High-risk, high-returns: biotech investing newsletter"
Frequently Asked Questions
How can I access the email archive for High Risk, High Returns?
You can find recent issues that have been published by High Risk, High Returns on Reletter by scrolling up to where it says Latest Issues. Tap on the link for any of the most recent emails or hit More Issues to see older ones.
How many subscribers does High Risk, High Returns have?
To see how many people subscribe to High Risk, High Returns, simply upgrade your Reletter account. We provide readership numbers and lots of other stats for this newsletter so you can decide if it's worth reaching out to.
How can I advertise in High Risk, High Returns?
Newsletter advertising can be extremely effective when it's done right. Before you pitch High Risk, High Returns as a potential sponsor or partner, make sure that you've done your research and checked its newsletter stats with Reletter.
Then, personalize one of our winning pitching templates and send it to the right person using the contact info provided.
How much does it cost to sponsor a publication like High Risk, High Returns?
Newsletter ad rates (or CPM) vary depending on many factors, including industry, number of subscribers, open rate, ad placement and more.
To find out how much an ad will cost, contact High Risk, High Returns using the contact information provided and ask for a copy of their media kit.
How can I find newsletters similar to High Risk, High Returns?
Scroll up to where it says Similar Newsletters to see other publications like High Risk, High Returns. You can also search our email newsletter directory to discover other newsletters that cover the topics you're interested in.
How do I contact High Risk, High Returns?
Reletter provides this newsletter's website URL above, where you will often find their contact information. We also provide links to associated social media accounts and pitching templates so you can reach out fast.